MA44207A - Immunoglobulines conjuguées cys80 - Google Patents

Immunoglobulines conjuguées cys80

Info

Publication number
MA44207A
MA44207A MA044207A MA44207A MA44207A MA 44207 A MA44207 A MA 44207A MA 044207 A MA044207 A MA 044207A MA 44207 A MA44207 A MA 44207A MA 44207 A MA44207 A MA 44207A
Authority
MA
Morocco
Prior art keywords
immunoglobulins
chain variable
cys80
immunoglobulin
light chain
Prior art date
Application number
MA044207A
Other languages
English (en)
Other versions
MA44207B1 (fr
Inventor
Earl Albone
Luigi Grasso
James Bradford Kline
Jared Spidel
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA44207A publication Critical patent/MA44207A/fr
Publication of MA44207B1 publication Critical patent/MA44207B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés de génération d'immunoglobulines conjuguées, le procédé comprenant : le décoiffage d'une cystéine à la position d'acide aminé 80 ("cys80") dans une région variable de chaîne légère d'une immunoglobuline, l'immunoglobuline comprenant une région variable de chaîne lourde et la région variable de chaîne légère ; et la conjugaison d'un composé réactif avec thiol avec cys80, le composé réactif avec thiol comprenant un groupe réactif avec thiol. L'invention concerne en outre des molécules de liaison d'antigène et des procédés de génération de celles-ci, des immunoglobulines ainsi que des molécules d'acide nucléique codant pour les immunoglobulines et des cellules hôtes comprenant les molécules d'acide nucléique, des immunoglobulines conjuguées, et des régions variables de chaîne légère pour utilisation dans une immunoglobuline conjuguée.
MA44207A 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80 MA44207B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19
PCT/US2016/038041 WO2016205618A1 (fr) 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80

Publications (2)

Publication Number Publication Date
MA44207A true MA44207A (fr) 2018-12-26
MA44207B1 MA44207B1 (fr) 2020-11-30

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44207A MA44207B1 (fr) 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80

Country Status (32)

Country Link
US (3) US10273310B2 (fr)
EP (2) EP3795591B1 (fr)
JP (2) JP6823606B2 (fr)
KR (1) KR102718129B1 (fr)
CN (1) CN107949575B (fr)
AU (1) AU2016280190B9 (fr)
CA (1) CA2989637C (fr)
CL (1) CL2017003273A1 (fr)
CO (1) CO2017013303A2 (fr)
CY (1) CY1123481T1 (fr)
DK (2) DK3795591T5 (fr)
ES (2) ES2967613T3 (fr)
HR (1) HRP20201489T1 (fr)
HU (2) HUE051315T2 (fr)
IL (1) IL256263B (fr)
LT (1) LT3310816T (fr)
MA (1) MA44207B1 (fr)
MD (1) MD3310816T2 (fr)
MX (1) MX389687B (fr)
MY (1) MY189024A (fr)
PE (1) PE20180498A1 (fr)
PH (2) PH12021551939A1 (fr)
PL (1) PL3310816T3 (fr)
PT (1) PT3310816T (fr)
RS (1) RS60943B1 (fr)
RU (1) RU2756101C2 (fr)
SG (1) SG10201913935RA (fr)
SI (1) SI3310816T1 (fr)
SM (1) SMT202000633T1 (fr)
UA (2) UA124830C2 (fr)
WO (1) WO2016205618A1 (fr)
ZA (2) ZA201708619B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090062A1 (fr) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament d'éribuline dirigés contre la mésothéline et procédés d'utilisation
CA3167317C (fr) * 2020-02-12 2025-05-27 Eli Lilly And Company Cristallisation d'anticorps ou de fragments de liaison à l'antigène
EP4161966A1 (fr) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Conjugués anticorps anti-bcma-médicament et procédés d'utilisation
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用
IL322523A (en) 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
WO2025199464A1 (fr) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament anti-trop2 et procédés d'utilisation
US20260042864A1 (en) * 2024-08-09 2026-02-12 Watchmaker Genomics, Inc. Hot-start antibodies for taq dna polymerase variant
WO2026044149A2 (fr) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthèse de combinaisons médicament-lieur pour conjugués anticorps-médicament
US20260139068A1 (en) 2024-08-21 2026-05-21 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use
WO2026071051A1 (fr) * 2024-09-27 2026-04-02 東レ株式会社 Agent réducteur pour éliminer la coiffe d'une immunoglobuline ou d'un fragment de liaison à l'antigène de celle-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936409T2 (de) * 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
CN100415765C (zh) * 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
WO2006017759A2 (fr) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Anticorps fixant le marqueur specifique des cellules endotheliales (tem1) et leurs utilisations
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
PT2164868E (pt) * 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
WO2009117531A1 (fr) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Conjugués auristatine-lieur de médicament
US20100260769A1 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
CA3220104A1 (fr) * 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
SG186451A1 (en) * 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
WO2014031476A1 (fr) * 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux spécifiques au domaine de la mésothéline et utilisation de ces derniers
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物

Also Published As

Publication number Publication date
US20160369011A1 (en) 2016-12-22
MY189024A (en) 2022-01-20
PH12021551939A1 (en) 2022-05-02
LT3310816T (lt) 2020-11-25
US20190202933A1 (en) 2019-07-04
CY1123481T1 (el) 2022-03-24
UA129321C2 (uk) 2025-03-19
CN107949575B (zh) 2022-03-08
CL2017003273A1 (es) 2018-12-21
WO2016205618A1 (fr) 2016-12-22
SMT202000633T1 (it) 2021-01-05
KR102718129B1 (ko) 2024-10-17
CA2989637C (fr) 2023-01-10
MD3310816T2 (ro) 2021-01-31
ZA202102093B (en) 2023-03-29
KR20180021807A (ko) 2018-03-05
IL256263A (en) 2018-02-28
EP3795591B1 (fr) 2023-09-27
JP2020178717A (ja) 2020-11-05
SI3310816T1 (sl) 2020-12-31
BR112017027252A2 (pt) 2018-08-28
RU2017146220A (ru) 2019-07-19
HK1252625A1 (en) 2019-05-31
PH12017502352B1 (en) 2023-05-26
RU2017146220A3 (fr) 2019-11-07
IL256263B (en) 2022-06-01
MX2017016674A (es) 2018-08-01
RS60943B1 (sr) 2020-11-30
EP3795591A1 (fr) 2021-03-24
PH12017502352A1 (en) 2018-06-25
NZ738496A (en) 2023-08-25
AU2016280190A1 (en) 2018-01-18
CN107949575A (zh) 2018-04-20
EP3310816B1 (fr) 2020-09-09
PE20180498A1 (es) 2018-03-09
ES2829251T3 (es) 2021-05-31
MA44207B1 (fr) 2020-11-30
JP7042876B2 (ja) 2022-03-28
US10273310B2 (en) 2019-04-30
AU2016280190B2 (en) 2022-04-28
SG10201913935RA (en) 2020-03-30
CA2989637A1 (fr) 2016-12-22
JP6823606B2 (ja) 2021-02-03
CO2017013303A2 (es) 2018-03-20
DK3795591T3 (da) 2024-01-02
ES2967613T3 (es) 2024-05-03
RU2756101C2 (ru) 2021-09-28
HRP20201489T1 (hr) 2020-12-11
JP2018526975A (ja) 2018-09-20
ZA201708619B (en) 2022-11-30
US11129904B2 (en) 2021-09-28
PT3310816T (pt) 2020-10-19
HUE064407T2 (hu) 2024-03-28
PL3310816T3 (pl) 2020-12-14
EP3310816A1 (fr) 2018-04-25
DK3310816T3 (da) 2020-10-12
US20230001004A1 (en) 2023-01-05
MX389687B (es) 2025-03-20
AU2016280190B9 (en) 2022-05-19
UA124830C2 (uk) 2021-12-01
HUE051315T2 (hu) 2021-03-01
DK3795591T5 (da) 2024-08-19

Similar Documents

Publication Publication Date Title
MA44207B1 (fr) Immunoglobulines conjuguées cys80
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
NZ739721A (en) Antigen binding constructs to target molecules
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EA201791742A1 (ru) Антитела, направленные против гена-3 активации лимфоцитов (lag-3)
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
EA201491827A1 (ru) Антитела против hla-b*27 и их применение
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2009006891A (es) Anticuerpos cd44.
MX372817B (es) Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1).
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX2021001672A (es) Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
MX2014010449A (es) Anticuerpos a metaloproteinasa de matriz 9.
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
EP4356972A3 (fr) Anticorps monoclonaux anti-annexine a2
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202092981A1 (ru) Антитела к l1cam и их применение
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations